Key Takeaways
- IDEAYA Biosciences unveiled impressive Phase 2/3 data for its darovasertib plus crizotinib combination in metastatic uveal melanoma patients
- The experimental combination achieved median progression-free survival of 6.9 months compared to 3.1 months with standard therapy
- Disease progression risk dropped by 58% among patients receiving the combination therapy
- The combination arm posted an overall response rate of 37.1% versus only 5.8% in the control group — with 5 patients achieving complete remission on the combo versus zero on standard care
- The company anticipates submitting a New Drug Application to the FDA during the latter half of 2026
Shares of IDEAYA Biosciences (IDYA) exploded higher during Monday’s premarket session following the biotech company’s announcement of compelling Phase 2/3 clinical trial data for its dual-drug regimen aimed at treating metastatic uveal melanoma — an uncommon and challenging eye cancer.
IDEAYA Biosciences, Inc., IDYA
The clinical study evaluated darovasertib in combination with crizotinib. Data revealed the pairing more than doubled the median time patients lived without their disease worsening when measured against current standard treatments.
Participants receiving the combination therapy achieved a median PFS of 6.9 months. Meanwhile, those on conventional treatment reached only 3.1 months. This outcome successfully met the study’s main objective.
The experimental regimen also reduced the likelihood of cancer progression by 58%. Such figures typically generate significant excitement among oncology-focused investors.
Impressive Results Across Secondary Measures
The trial’s secondary measures were equally compelling. The overall response rate registered at 37.1% for patients on the darovasertib combination, dramatically outperforming the mere 5.8% seen with conventional therapy.
Five individuals treated with the combination achieved complete tumor elimination. In contrast, the standard-care group saw none whatsoever.
The median duration patients maintained their response in the combination group stood at 6.8 months. Researchers characterized the treatment as well-tolerated with safety concerns that could be effectively managed.
Early signals also pointed toward potential overall survival advantages for the combination compared to existing treatments, although complete data regarding this measure hasn’t yet fully developed.
Metastatic uveal melanoma patients have traditionally faced extremely limited effective therapeutic options. These findings establish darovasertib as a potentially groundbreaking first-in-class treatment for this indication.
Regulatory Submission Targeted for Second Half 2026
IDEAYA announced its intention to file a New Drug Application with the FDA during the second half of 2026, leveraging these promising trial outcomes.
This schedule suggests a potential regulatory approval decision could arrive sometime throughout 2027, contingent upon how quickly the FDA completes its evaluation.
IDYA stock climbed as high as 26.36% during premarket activity, touching $38.60, based on Benzinga Pro information. Some earlier tracking showed the advance at approximately 15%, with shares changing hands around $35.
The equity had already been hovering near its 52-week peak of $41.02 prior to Monday’s news. Throughout the preceding 12 months, IDYA has climbed approximately 78%.
Broader equity markets displayed weakness Monday morning, with S&P 500 futures declining roughly 0.6% during the same premarket period.
IDEAYA intends to share comprehensive trial findings at a forthcoming medical conference, with additional information anticipated later during 2026.
